Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC
Go back to Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC| (NASDAQ: TNYA) | Delayed: 0.70 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.70 | 52 Week High | $ | |||
| Open | $0.70 | 52 Week Low | $ | |||
| Day High | $0.70 | P/E | N/A | |||
| Day Low | $0.70 | EPS | $ | |||
| Volume | 57,305 | |||||
